Allife Medical Science and Technology Co., Ltd.
16
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke
Role: lead
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia
Role: lead
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Role: lead
Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer
Role: lead
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Role: lead
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Role: lead
A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells
Role: lead
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Role: lead
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors
Role: lead
A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
Role: lead
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Role: lead
iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations
Role: lead
A Study of Autologous Induced Islet Body With Type 1 Diabetes
Role: lead
A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke
Role: lead
A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke
Role: lead
Study of BCMA CAR-T in Multiple Myeloma
Role: lead
All 16 trials loaded